Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the ...
(WorldNews Business)

LEIDEN, the Netherlands & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 21, 2020-- Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia´s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use. This press release features multimedia. View the full release here:...